Filtered By:
Source: Circulation
Condition: Bleeding

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 151 results found since Jan 2013.

Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation.
CONCLUSIONS: -In general practice settings, dabigatran was associated with reduced risk of ischemic stroke, intracranial hemorrhage, and death, and increased risk of major gastrointestinal hemorrhage compared with warfarin in elderly patients with non-valvular AF. These associations were most pronounced in patients treated with dabigatran 150 mg twice daily, whereas the association of 75 mg twice daily with study outcomes was indistinguishable from warfarin except for a lower risk of intracranial hemorrhage with dabigatran. PMID: 25359164 [PubMed - as supplied by publisher]
Source: Circulation - October 30, 2014 Category: Cardiology Authors: Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA Tags: Circulation Source Type: research

Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial.
CONCLUSIONS: -GDF-15 is a risk factor for major bleeding, mortality and stroke in atrial fibrillation. The prognostic value for major bleeding and death remained even in the presence of NT-proBNP and hs-TnI. Clinical Trial Registration Information-www.clinicaltrials.gov. Identifier: NCT00412984. PMID: 25294786 [PubMed - as supplied by publisher]
Source: Circulation - October 7, 2014 Category: Cardiology Authors: Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A, on behalf of the ARISTOTLE Investigators Tags: Circulation Source Type: research

Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration.
CONCLUSIONS: -Aspirin after anticoagulant treatment reduces the overall risk of recurrence by more than a third in a broad cross-section of patients with a first unprovoked VTE, without significantly increasing the risk of bleeding. CLINICAL TRIAL REGISTRATION INFORMATION: -National Health and Medical Research Council (Australia) (ACTRN12611000684921 at www.anzctr.org.au). PMID: 25156992 [PubMed - as supplied by publisher]
Source: Circulation - August 25, 2014 Category: Cardiology Authors: Simes J, Becattini C, Agnelli G, Eikelboom JW, Kirby AC, Mister R, Prandoni P, Brighton TA, for the INSPIRE (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism) Study Investigators Tags: Circulation Source Type: research

Efficacy and Safety of Rivaroxaban Compared with Warfarin among Elderly Patients with Nonvalvular Atrial Fibrillation in the ROCKET AF Trial.
CONCLUSIONS: -Elderly patients had higher stroke and major bleeding rates than younger patients, but the efficacy and safety of rivaroxaban relative to warfarin did not differ with age, supporting rivaroxaban as an alternative for the elderly. Clinical Trial Registration Information-ClinicalTrials.gov; Unique Identifier: NCT00403767. PMID: 24895454 [PubMed - as supplied by publisher]
Source: Circulation - June 3, 2014 Category: Cardiology Authors: Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA, on behalf of the ROCKET AF Steering Committee and Investigators Tags: Circulation Source Type: research

Periprocedural Stroke and Bleeding Complications in Patients undergoing Catheter Ablation of Atrial Fibrillation with Different Anticoagulation Management: Results from the "COMPARE" Randomized Trial.
CONCLUSIONS: This is the first randomized study showing that performing catheter ablation of AF without warfarin discontinuation reduces the occurrence of peri-procedural stroke and minor bleeding complications when compared to bridging with low molecular weight heparin. CLINICAL TRIAL REGISTRATION INFORMATION: www.clinicaltrials.gov/. Identifier: NCT01006876. PMID: 24744272 [PubMed - as supplied by publisher]
Source: Circulation - April 17, 2014 Category: Cardiology Authors: Di Biase L, Burkhardt D, Santangeli P, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, Reddy M, Hao S, Hongo R, Beheiry S, Zagrodzky J, Bai R, Mohanty S, Elayi CS, Forleo G, Pelargonio G, Narducci ML, Dello Rus Tags: Circulation Source Type: research

High-On Treatment Platelet Reactivity as a Risk Factor for Secondary Prevention after Coronary Stent Revascularization: A Landmark Analysis of the ARCTIC Study.
CONCLUSIONS: Detection of platelet hyper-reactivity by platelet function testing in patients undergoing coronary stenting with further therapeutic adjustment does not reduce ischemic recurrences after intervention. On-treatment platelet hyper-reactivity cannot be considered as a risk factor requiring intervention for secondary prevention after percutaneous coronary revascularization. CLINICAL TRIAL REGISTRATION INFORMATION: http://clinicaltrials.gov; Identifier: NCT00827411. PMID: 24718568 [PubMed - as supplied by publisher]
Source: Circulation - April 9, 2014 Category: Cardiology Authors: Montalescot G, Rangé G, Silvain J, Bonnet JL, Boueri Z, Barthélémy O, Cayla G, Belle L, Van Belle E, Cuisset T, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Et Tags: Circulation Source Type: research

Lack of Concordance between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
CONCLUSIONS: There is little agreement between provider-assessed risk and empirical scores in AF. These differences may explain, in part, current divergence of anticoagulation treatment decisions from guideline recommendations. CLINICAL TRIAL REGISTRATION INFORMATION: clinicaltrials.gov Identifier: NCT01165710. PMID: 24682387 [PubMed - as supplied by publisher]
Source: Circulation - March 29, 2014 Category: Cardiology Authors: Steinberg BA, Kim S, Thomas L, Fonarow GC, Hylek E, Ansell J, Go AS, Chang P, Kowey P, Gersh BJ, Mahaffey KW, Singer DE, Piccini JP, Peterson ED, on behalf of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigat Tags: Circulation Source Type: research

Comparing the Imperfect with the Imperfect: The Imprecise Science of Assessing the Risk and Benefits of Anticoagulation in Atrial Fibrillation.
Abstract Atrial Fibrillation (AF) is the most common arrhythmia in the United States, with approximately 7 million Americans estimated to have AF by 2020.(1,2) A major cause for morbidity and mortality in AF is stroke. Pharmacologic therapy for the prevention of stroke has undergone a renaissance with the advent of newer oral anticoagulants (NOACs) that are safe and effective alternatives to warfarin. However, the decision to initiate anticoagulation remains a subjective assessment of risks versus benefits. Although guided by well-validated risk scores for stroke and bleeding,(3,4,5) real world decisions on antico...
Source: Circulation - March 29, 2014 Category: Cardiology Authors: Ellenbogen KA, Tan AY Tags: Circulation Source Type: research

Outcomes of Temporary Interruption of Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Results from ROCKET AF.
CONCLUSIONS: TI of oral anticoagulation is common and associated with substantial stroke risks and bleeding risks that were similar among patients treated with rivaroxaban or warfarin. Further investigation is needed to determine the optimal management strategy in AF patients requiring TI of anticoagulation. CLINICAL TRIAL REGISTRATION INFORMATION: www.ClinicalTrials.gov. Identifier: NCT00403767. PMID: 24552831 [PubMed - as supplied by publisher]
Source: Circulation - February 19, 2014 Category: Cardiology Authors: Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, Spyropoulos AC, Hankey GJ, Singer DE, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Becker RC, on behalf of the ROCKET AF Investigators Tags: Circulation Source Type: research

Warfarin Use and the Risk for Stroke and Bleeding in Patients with Atrial Fibrillation Undergoing Dialysis.
CONCLUSIONS: Our results suggest that warfarin use is not beneficial in reducing stroke risk but is associated with a higher bleeding risk in patients with AF undergoing dialysis. PMID: 24452752 [PubMed - as supplied by publisher]
Source: Circulation - January 22, 2014 Category: Cardiology Authors: Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L Tags: Circulation Source Type: research

Efficacy and Safety of Dabigatran Compared with Warfarin in Relation to Baseline Renal Function in Patients with Atrial Fibrillation: A RE-LY Trial Analysis.
CONCLUSIONS: The efficacy of both dosages of dabigatran was consistent with the overall trial irrespective of renal function. However, with the CKD-EPI and MDRD equations both dabigatran doses displayed significantly lower rates of major bleeding in patients with GFR ≥80 ml/min. CLINICAL TRIAL REGISTRATION INFORMATION: www.clinicaltrials.gov. Identifier: NCT00262600. PMID: 24323795 [PubMed - as supplied by publisher]
Source: Circulation - December 9, 2013 Category: Cardiology Authors: Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L Tags: Circulation Source Type: research

Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation: A Randomized Controlled Trial.
CONCLUSIONS: Among patients who were on 12-month dual antiplatelet therapy without complications, an additional 24 months of dual antiplatelet therapy versus aspirin alone did not reduce the risk of the composite end point of death from cardiac causes, myocardial infarction or stroke. CLINICAL TRIAL REGISTRATION INFORMATION: http://www.clinicaltrials.gov. Identifier: NCT01186146. PMID: 24097439 [PubMed - as supplied by publisher]
Source: Circulation - October 4, 2013 Category: Cardiology Authors: Lee CW, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Han S, Lee SG, Seong IW, Rha SW, Jeong MH, Lim DS, Yoon JH, Hur SH, Choi YS, Yang JY, Lee NH, Kim HS, Lee BK, Kim KS, Lee SU, Chae JK, Cheong SS, Suh IW, Park HS, Nah DY, Jeon DS, Seung KB, Lee K, Tags: Circulation Source Type: research

Early Dual versus Mono Antiplatelet Therapy for Acute Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack: An Updated Systematic Review and Meta-Analysis.
CONCLUSIONS: For patients with acute non-cardioembolic ischemic stroke or TIA, dual therapy was more effective than monotherapy in reducing risks of early recurrent stroke. The results of the CHANCE study are consistent with previous studies done in other parts of the world. PMID: 24030500 [PubMed - as supplied by publisher]
Source: Circulation - September 12, 2013 Category: Cardiology Authors: Wong KS, Wang Y, Leng X, Mao C, Tang J, Bath PM, Markus HS, Gorelick PB, Liu L, Lin W, Wang Y Tags: Circulation Source Type: research

Elderly Patients with Acute Coronary Syndromes Managed Without Revascularization Insights into the Safety of Long-Term Dual Antiplatelet Therapy with Reduced-Dose Prasugrel vs. Standard-Dose Clopidogrel.
CONCLUSIONS: Older age is associated with substantially increased long-term cardiovascular risk and bleeding among medically managed ACS patients, with no differences in ischemic or bleeding outcomes with reduced-dose prasugrel vs. clopidogrel in elderly patients. No significant interaction among weight, pharmacodynamic response, and bleeding risk was observed between reduced-dose prasugrel vs. clopidogrel in elderly patients. CLINICAL TRIAL REGISTRATION INFORMATION: http://clinicaltrials.gov/ct2/home. Identifier: NCT0069999. PMID: 23852610 [PubMed - as supplied by publisher]
Source: Circulation - July 12, 2013 Category: Cardiology Authors: Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW Tags: Circulation Source Type: research

The Long Term Multi-Center Observational Study of Dabigatran Treatment in Patients with Atrial Fibrillation: (RELY-ABLE) Study.
CONCLUSIONS: During 2.3 years continued treatment with dabigatran after RE-LY, there was a higher rate of major bleeding with dabigatran 150 mg twice daily compared to 110 mg, and similar rates of stroke and death. CLINICAL TRIAL REGISTRATION INFORMATION: Clinicaltrials.gov; Identifier: NCT00808067. PMID: 23770747 [PubMed - as supplied by publisher]
Source: Circulation - June 14, 2013 Category: Cardiology Authors: Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom JW, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn Tags: Circulation Source Type: research